176 related articles for article (PubMed ID: 6414687)
1. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Cancer Treat Rev; 1983 Sep; 10 Suppl A():1-192. PubMed ID: 6414687
[No Abstract] [Full Text] [Related]
2. Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-58. PubMed ID: 3102087
[No Abstract] [Full Text] [Related]
3. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Czownicki Z; Utracka-Hutka B
Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
[No Abstract] [Full Text] [Related]
4. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Brock N; Pohl J; Stekar J
J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and Mesna in advanced malignancies.
Li GC; Brock N; Li JQ; Guan ZZ; He YJ
Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
[No Abstract] [Full Text] [Related]
6. Ifosfamide and mesna.
Schoenike SE; Dana WJ
Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Brock N; Stekar J
Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
Fosså SD; Talle K
Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Burkert H; Schnitker J; Fichtner E
MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422
[TBL] [Abstract][Full Text] [Related]
10. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
Sangster G; Kaye SB; Calman KC; Dalton JF
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):435-6. PubMed ID: 6423391
[No Abstract] [Full Text] [Related]
11. [The use of holoxan (iphosphamide) in malignant tumors].
Perevodchikova NI; Orel NF; Trofimova NV
Vopr Onkol; 1990; 36(9):1085-8. PubMed ID: 2122594
[TBL] [Abstract][Full Text] [Related]
12. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Falkson G; Van Dyk JJ; Stapelberg R; Falkson HC
Cancer Chemother Pharmacol; 1982; 9(2):81-4. PubMed ID: 6816479
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
De Forges A; Droz JP; Ghosn M; Theodore C
Cancer Treat Rep; 1987 Nov; 71(11):1103. PubMed ID: 3119203
[No Abstract] [Full Text] [Related]
14. Nursing implications in the administration of ifosfamide and mesna.
Richters JE
Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
[No Abstract] [Full Text] [Related]
15. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
16. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
Brock N; Pohl J; Stekar J; Scheef W
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
[TBL] [Abstract][Full Text] [Related]
17. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Marti C; Steiner R; Viollier AF
Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
[TBL] [Abstract][Full Text] [Related]
18. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Brock N; Pohl J
IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Klein HO; Wickramanayake PD; Coerper C; Christian E; Pohl J; Brock N
Cancer Treat Rev; 1983 Sep; 10 Suppl A():167-73. PubMed ID: 6414691
[No Abstract] [Full Text] [Related]
20. Clinical overview of mesna.
Burkert H
Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
